Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery.
Apoptosis
; 24(5-6): 529-537, 2019 06.
Article
en En
| MEDLINE
| ID: mdl-30879165
Although new cancer therapeutics are discovered at a rapid pace, lack of effective means of delivery and cancer chemoresistance thwart many of the promising therapeutics. We demonstrate a method that confronts both of these issues with the light-activated delivery of a Bcl-2 functional converting peptide, NuBCP-9, using hollow gold nanoshells. This approach has shown not only to increase the efficacy of the peptide 30-fold in vitro but also has shown to reduce paclitaxel resistant H460 lung xenograft tumor growth by 56.4%.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Sistemas de Liberación de Medicamentos
/
Proteínas Proto-Oncogénicas c-bcl-2
/
Nanocáscaras
/
Oro
/
Antineoplásicos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Apoptosis
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Países Bajos